Zalbin FDA Approval Status
FDA Approved: No
Brand name: Zalbin
Generic name: albinterferon alfa-2b
Company: Human Genome Sciences, Inc.
Treatment for: Hepatitis C
Zalbin (albinterferon alfa-2b) is a genetic fusion of human albumin and interferon alfa intended for the treatment of chronic hepatitis C.In October 2010, Human Genome Sciences, Inc. (HGS) announced the receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for Zalbin (albinterferon alfa-2b). HGS and Novartis have decided not to develop Zalbin further.
Development Timeline for Zalbin
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.